Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

Asia’s leading multi-asset exchange

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Equity Bottom-Up

<h2>10 Questions for Singapore O&amp;G Limited</h2>
<p><strong>Company Overview</strong><br>Established since 2011, Singapore O&amp;G Ltd. (“SOG”) is a healthcare service provider dedicated towards delivering premier medical services to women’s and children’s health and wellness at affordable prices. The Group’s clinics, under its four operating segments of Obstetrics and Gynaecology (“O&amp;G”), Cancer-related, Dermatology and Paediatrics, are strategically located throughout Singapore to provide easy access to its patients. <a href="https://www.sgx.com/securities/equities/1D8" target="_blank" rel="noopener">Link to StockFacts company page</a></p>
<ol>
<li><strong>Describe SOG’s recent financial performances</strong></li>
</ol>
<ul>
<li>SOG has posted stable revenue growth over the years since our IPO in 2015. Our profit from operations has doubled from S$6.1 million in 2015 to S$12.5 million in 2019</li>
<li>Despite the COVID-19 pandemic, coupled with the suspension of non-essential medical services in April and May 2020, the Group posted revenue of S$17.9 million for 1H 2020 which is a slight decline of 4.2% as compared to S$18.7 million in 1H 2019. This is largely attributed to the performance of our O&amp;G and Paediatricssegments.</li>
<li>During this challenging time, the Group posted a net profit after tax of S$3.8 million for 1H 2020 (which is a decrease of 21.4% from S$4.8 million in 1H 2019).</li>
<li>The Group paid out an interim dividend for 1H 2020 of 0.50 Singapore cents per share, maintaining a dividend payout ratio of about 62% of the Group’s net profit after tax.</li>
</ul>
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/182/061/original/image_86408737521610426849792.png?1610426851" class="editor-image img-responsive" data-smartkarma-image-id="182061"></figure>

10 Questions for Singapore O&amp;G Limited
Company Overview Established since 2011, Singapore O&amp;G Ltd. (“SOG”) is a healthcare service provider dedicated towards delivering premier medical services to women’s and children’s health and wellness at affordable prices. The Group’s clinics, under its four operating segments of Obstetrics and Gynaecology (“O&amp;G”), Cancer-related, Dermatology and Paediatrics, are strategically located throughout Singapore to provide easy access to its patients. Link to StockFacts company page

Describe SOG’s recent financial performances


SOG has posted stable revenue growth over the years since our IPO in 2015. Our profit from operations has doubled from S$6.1 million in 2015 to S$12.5 million in 2019
Despite the COVID-19 pandemic, coupled with the suspension of non-essential medical services in April and May 2020, the Group posted revenue of S$17.9 million for 1H 2020 which is a slight decline of 4.2% as compared to S$18.7 million in 1H 2019. This is largely attributed to the performance of our O&amp;G and Paediatricssegments.
During this challenging time, the Group posted a net profit after tax of S$3.8 million for 1H 2020 (which is a decrease of 21.4% from S$4.8 million in 1H 2019).
The Group paid out an interim dividend for 1H 2020 of 0.50 Singapore cents per share, maintaining a dividend payout ratio of about 62% of the Group’s net profit after tax.



10 in 10 with Singapore O&G - Healthcare Specialist for Women & Children